

SCIENTIFIC REPORTS

OPEN

Effect of carnosine supplementation on the plasma lipidome in overweight and obese adults: a pilot randomised controlled trial

Received: 25 August 2017

Accepted: 22 November 2017

Published online: 12 December 2017

Estifanos Baye¹, Jozef Ukropec², Maximilian PJ de Courten³, Silvia Vallova⁴, Patrik Krumpolec², Timea Kurdiová², Giancarlo Aldini⁵, Barbara Ukropcova^{2,4} & Barbora de Courten¹

Carnosine has been shown to reduce oxidation and glycation of low density lipoprotein hence improving dyslipidaemia in rodents. The effect of carnosine on human plasma lipidome has thus far not been investigated. We aimed to determine whether carnosine supplementation improves the plasma lipidome in overweight and obese individuals. Lipid analysis was performed by liquid chromatography mass spectrometry in 24 overweight and obese adults: 13 were randomly assigned to 2 g carnosine daily and 11 to placebo, and treated for 12 weeks. Carnosine supplementation maintained trihexosylceramide (0.01 ± 0.19 vs -0.28 ± 0.34 nmol/ml, $p = 0.04$), phosphatidylcholine (77 ± 167 vs -81 ± 196 nmol/ml, $p = 0.01$) and free cholesterol (20 ± 80 vs -69 ± 80 nmol/ml, $p = 0.006$) levels compared to placebo. Trihexosylceramide was inversely related with fasting insulin ($r = -0.6$, $p = 0.002$), insulin resistance ($r = -0.6$, $p = 0.003$), insulin secretion ($r = -0.4$, $p = 0.05$) and serum carnosinase 1 activity ($r = -0.3$, $p = 0.05$). Both phosphatidylcholine and free cholesterol did not correlate with any cardiometabolic parameters. Our data suggest that carnosine may have beneficial effects on the plasma lipidome. Future larger clinical trials are needed to confirm this.

Dyslipidaemia is one of the modifiable cardiometabolic risk factors that has been shown to play a significant role in the development of insulin resistance, type 2 diabetes (T2DM) and cardiovascular diseases (CVD)¹⁻³. In clinical practice, dyslipidaemia is usually defined as increased total cholesterol and low density lipoprotein (LDL) with decreased high density lipoprotein (HDL) levels³. This provides a very narrow snapshot of the dynamic processes involved in lipid metabolism⁴. In addition, these traditional clinical measures are not sufficient to explain the complexity of lipid metabolism which are known to be altered in obese individuals, patients with metabolic syndrome and T2DM, and individuals with high cardiovascular risk⁵⁻⁷. Lipidomics approach can provide new insight into the lipid metabolism by offering a chance to examine the lipid classes and species in plasma^{4,5}. Lipidomics is focused on the comprehensive identification and quantification of all lipids from serum, plasma, tissue, whole organism or cell⁸. Lipid profiling has shown promising results in the identification of metabolic biomarkers, understanding the mechanisms of lipid metabolism, and diagnosis of various conditions and diseases such as obesity, metabolic syndrome, T2DM and CVD as well as in determining responses to therapeutic interventions⁹⁻¹². Recently, plasma lipid classes and species have been shown to associate with T2DM and CVD^{5,13-15}.

Carnosine is an over-the-counter food supplement and it has been shown to prevent and treat several chronic diseases¹⁶ through its anti-inflammatory, antioxidant, anti-glycation, anti-ischaemic and chelating properties¹⁷⁻¹⁹. We have previously demonstrated that carnosine supplementation prevented worsening of insulin resistance in

¹Monash Centre for Health Research and Implementation, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia. ²Institute of Experimental Endocrinology, Biomedical Research Centre, Slovak Academy of Sciences, Bratislava, Slovakia. ³Centre for Chronic Disease, College of Health and Biomedicine, Victoria University, Melbourne, Australia. ⁴Institute of Pathological Physiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia. ⁵Department of Pharmaceutical Sciences, Università degli Studi di Milano, Milan, Italy. Correspondence and requests for materials should be addressed to B.d.C. (email: barbora.decourten@monash.edu)

Parameters	Carnosine (n = 13)	Placebo (n = 11)	P-value
Sex	F = 3, M = 10	F = 3, M = 8	
Age (years)	42 ± 6	43 ± 9	0.73
Body mass index (kg/m ²)	30.4 ± 4.5	32.3 ± 4.6	0.32
Waist-to-hip ratio	0.89 ± 0.06	0.88 ± 0.06	0.74
Systolic BP (mm Hg)	117.1 ± 8.8	125.1 ± 13.3	0.09
Diastolic BP (mm Hg)	76.1 ± 5.5	83.1 ± 9.2	0.06
Fasting glucose (mmol/l)	5.4 ± 0.46	5.3 ± 0.50	0.60
2 h glucose (mmol/l)	6.6 ± 2.0	7.5 ± 2.4	0.35
Fasting insulin (mU/l)	12.4 ± 7.3	14.3 ± 5.4	0.49
2 h insulin (mU/l)	109.5 ± 75.9	127.5 ± 84.6	0.58
HOMA-IR	3.0 ± 2.0	3.2 ± 1.2	0.69
HOMA-B	136.3 ± 55.1	182.1 ± 89.9	0.14
Total cholesterol (mmol/l)	5.4 ± 0.9	5.3 ± 0.8	0.77
High density lipoprotein (mmol/l)	1.2 ± 0.3	1.2 ± 0.2	0.97
Triglycerides (mmol/l)	1.8 ± 1.0	1.5 ± 0.5	0.41
C-reactive protein (mg/l)	3.4 ± 2.9	4.4 ± 4.6	0.50
Adiponectin (µmol/ml)	5.9 ± 3.3	5.8 ± 1.8	0.96
Urinary carnosine levels (nmol/ml)	8.9 ± 6.1	8.0 ± 6.3	0.73
Carnosinase 1 activity (µM)	1.8 ± 0.8	2.1 ± 0.6	0.39
Fat preference score (high fat/low fat score)	0.94 ± 0.13	0.86 ± 0.12	0.12
REE (kcal/kg/day)	32.3 ± 4.6	32.3 ± 6.5	0.99

Table 1. Participant baseline characteristics. Means and standard deviations were reported. Independent t-tests were computed to determine the p-value. BP, blood pressure; HOMA-B, homeostatic model of assessment of insulin secretion; HOMA-IR, homeostatic model of assessment of insulin resistance; REE, resting energy expenditure.

non-diabetic overweight and obese individuals, but did not change plasma lipid profiles such as total and HDL cholesterol, and triglycerides²⁰. However, in both diabetic and non-diabetic rodents, carnosine has been shown to improve dyslipidaemia, reduce oxidation and glycation of LDL and reduce development of atherosclerosis^{21,22}. We have therefore hypothesised that carnosine supplementation may have beneficial effect on the plasma lipids in overweight and obese individuals which will be related to cardiometabolic parameters.

Results

Baseline characteristics. Twenty-four participants (13 in carnosine, 11 placebo group) were included in this analysis. Of these, six of them were females (3 in each group). The overall mean age of the participants' were 43 ± 7 years with a body mass index of 31 ± 4.5 kg/m². Baseline anthropometric and blood pressure measurements, glucose parameters, lipid profiles, inflammatory markers, urinary carnosine levels, and serum carnosinase activity and content were not different between the groups (Table 1). Dietary fat preference and resting energy expenditure did not differ between the groups. Similarly, levels of lipid classes at baseline were not different in carnosine and placebo groups (Table 2).

Effect of carnosine supplementation on the plasma lipidome. Carnosine supplementation maintained the levels of trihexosylceramide (THC) (mean change from baseline ± standard deviation: 0.01 ± 0.19 versus -0.28 ± 0.34 nmol/ml, p = 0.04) and phosphatidylcholine (PC) (77 ± 167 versus -81 ± 196 nmol/ml, p = 0.01) lipid classes compared to placebo. Free cholesterol (COH) was also preserved in the carnosine group than placebo (20 ± 80 versus -69 ± 80 nmol/ml, p = 0.006). None of the other lipid classes showed changes between the groups (Table 2).

Relationship between lipid classes and cardiometabolic parameters. Change in THC was inversely related with change in fasting insulin levels (r = -0.6, p = 0.002), HOMA-IR (r = -0.6, p = 0.003), HOMA-B (r = -0.4, p = 0.05) and serum carnosinase 1 activity (r = -0.5, p = 0.01). These associations except for HOMA-B were significant after adjustment for age, sex, and change in BMI (all p < 0.03). THC did not correlate with other cardiometabolic parameters and carnosine measurements (all p > 0.2). PC was positively correlated with BMI (r = 0.4, p = 0.04), however this relationship was not significant after adjusting either for age or sex (all p > 0.05). Both PC and COH did not associate with anthropometric measures, metabolic or cardiovascular parameters, and urinary carnosine levels as well as serum carnosinase 1 activity/content (all p > 0.1). THC, PC and COH were not related either with dietary fat preference or resting energy expenditure (all p > 0.05).

Lipid class	Carnosine group (n = 13)		Placebo group (n = 11)		P*	P [#]
	Baseline	Change from baseline	Baseline	Change from baseline		
dhCer	0.93 ± 0.22	0.19 ± 0.24	0.99 ± 0.31	0.02 ± 0.27	0.53	0.15
Cer	7.26 ± 1.47	0.06 ± 1.03	6.65 ± 1.24	-0.22 ± 0.63	0.28	0.08
MHC	19.22 ± 4.34	-0.78 ± 3.54	16.28 ± 3.57	-0.86 ± 1.09	0.08	0.16
DHC	9.29 ± 1.82	-0.66 ± 1.13	8.60 ± 1.53	-0.95 ± 1.45	0.33	0.21
THC	1.78 ± 0.43	0.01 ± 0.19	1.98 ± 0.45	-0.28 ± 0.34	0.26	0.04
GM3	5.34 ± 1.27	-0.09 ± 0.55	4.99 ± 1.04	-0.38 ± 0.56	0.48	0.20
SM	421.38 ± 73.29	-9.74 ± 36.72	425.35 ± 98.92	-31.23 ± 54.22	0.91	0.10
PC	1821.96 ± 264.12	77.28 ± 16.70	1801.78 ± 282.53	-81.27 ± 196.02	0.85	0.01
PC(O)	82.05 ± 12.17	1.27 ± 14.86	90.43 ± 15.54	-3.59 ± 11.64	0.15	0.84
PC(P)	41.35 ± 5.98	0.49 ± 5.81	45.35 ± 11.45	-2.26 ± 8.07	0.28	0.67
LPC	118.67 ± 14.52	-5.15 ± 19.41	105.99 ± 24.54	-10.20 ± 14.21	0.13	0.14
LPC(O)	1.71 ± 0.11	-0.14 ± 0.25	1.69 ± 0.20	-0.01 ± 0.13	0.85	0.68
PE	32.63 ± 9.51	-0.046 ± 5.91	31.51 ± 11.16	-0.10 ± 7.29	0.79	0.81
PE(O)	2.69 ± 1.00	0.14 ± 1.13	2.92 ± 1.00	-0.08 ± 0.97	0.59	0.82
PE(P)	29.20 ± 5.41	2.79 ± 8.09	31.66 ± 5.41	0.19 ± 7.33	0.27	0.76
LPE	7.18 ± 1.47	-0.16 ± 1.73	6.41 ± 1.26	-0.35 ± 0.97	0.18	0.17
PI	44.22 ± 12.45	-1.71 ± 6.40	39.95 ± 8.58	-2.06 ± 6.43	0.34	0.27
LPI	0.74 ± 0.17	0.098 ± 0.19	0.73 ± 0.17	0.06 ± 0.13	0.88	0.49
PS	9.07 ± 3.09	0.05 ± 2.56	10.39 ± 4.53	-1.77 ± 5.89	0.40	0.55
PG	0.22 ± 0.13	-0.01 ± 0.07	0.18 ± 0.008	-0.01 ± 0.07	0.39	0.49
CE	1345.49 ± 251.06	5.49 ± 21.05	1254.97 ± 206.26	-22.47 ± 174.38	0.35	0.58
COH	896.96 ± 131.96	20.05 ± 79.62	933.82 ± 166.13	-68.56 ± 79.71	0.55	0.006
DG	40.86 ± 24.67	1.03 ± 15.39	35.88 ± 16.95	-0.04 ± 20.03	0.57	0.78
TG	347.22 ± 175.29	19.40 ± 129.72	289.03 ± 93.68	-4.31 ± 9.13	0.33	0.58

Table 2. Effect of carnosine supplementation on the plasma lipidome. All values are in nmol/ml. Means and standard deviations were reported. *Independent t-tests were conducted to compare the baseline differences between the groups. #Analysis of covariance were performed to determine between-group treatment differences. dhCer, dihydroceramide; Cer, ceramide; MHC, monohexosylceramide; DHC, dihexosylceramide; THC, trihexosylceramide; GM3, GM3 ganglioside; SM, sphingomyelin; PC, phosphatidylcholine; PC(O), alkylphosphatidylcholine; PC(P), alkenylphosphatidylcholine; PC, lysophosphatidylcholine; LPC(O), lysoalkylphosphatidylcholine; PE, phosphatidylethanolamine; PE(O), alkylphosphatidylethanolamine; PE(P), alkenylphosphatidylethanolamine; LPE, lysophosphatidylethanolamine; PI, phosphatidylinositol; LPI, lysophosphatidylinositol; PS, phosphatidylserine; PG, phosphatidylglycerol; CE, cholesterol ester; COH, free cholesterol; DG, diacylglycerol; TG, triacylglycerol.

Discussion

We measured the effect of carnosine supplementation on the plasma lipidome in non-diabetic overweight and obese adults from a randomised double-blind placebo controlled pilot trial. We have demonstrated that supplementation with 2 g carnosine daily for 12 weeks resulted in changes in plasma lipidome which were associated with improved insulin sensitivity and secretion as well as serum carnosinase 1 activity.

We have demonstrated that THC levels were maintained after carnosine supplementation compared to placebo, which showed a relative increase in the carnosine group. This finding is consistent with the recent data that showed higher levels of THC after lifestyle intervention (diet and exercise) in patients with metabolic syndrome compared to dietary intervention only and no intervention²³. Treatment with RVX-208, first-in-class BET inhibitor with apolipoprotein A-I inducing effects, has also been shown to increase THC levels in prediabetes males compared to placebo²⁴. THC constitutes the main components of cell membranes and has been suggested to have beneficial roles in signal transmission, cell adhesion, growth factor regulation and protein transport²⁵. These mechanisms have been shown to play a role in the development of insulin resistance and T2DM²⁶. Meikle and colleagues have reported that THC was inversely associated with obesity²⁷, plasma glucose level and decreased with prediabetes and T2DM¹⁴. Lower levels of THC was also observed in people with metabolic syndrome²³. Similarly, we have found that THC was inversely associated with fasting insulin, insulin resistance, and insulin secretion. We showed, however, no association with other glycaemic measures (fasting glucose, 2 h glucose and insulin levels), anthropometric measures and inflammatory markers. This is likely because our study population was overweight and obese but did not have with other features of metabolic syndrome. Importantly, THC was inversely associated with serum carnosinase 1 activity. Low serum carnosinase 1 activity increases circulating carnosine in humans²⁸. We did not, however, find any association between THC and urinary carnosine levels. Nonetheless, we have previously shown that supplementation with carnosine increased the level of carnosine in urine and prevented worsening of insulin sensitivity in non-diabetic overweight and obese adults²⁰. Therefore, the observed effect of carnosine on THC levels may suggest its promising effect in normalising the plasma lipid profile in high risk groups which may have a role in preventing the development of insulin resistance and T2DM.

We report that supplementation with carnosine, as compared to placebo, improved plasma PC levels in overweight and obese, otherwise healthy individuals. In line with this, a study that involved older patients with established CVD showed an increased plasma PC levels after treatment with rosuvastatin²⁹. A single session of acute exercise has also tended to increase muscle PC levels in patients with T2DM³⁰. PC is a major constituent of the plasma membrane and a key element of very-low-density lipoproteins. It serves as a precursor of signalling molecules³¹ and plays a role in exporting triglycerides to the organs³². A deficiency of PC in the secretory pathway or in the nascent particle may limit the secretion of very-low-density lipoproteins and leads to the accumulation of hepatic triglycerides³². Low cellular PC levels have been shown to activate sterol regulatory element-binding protein-1 (SREBP1), a transcription factor involved in glucose metabolism, thereby contribute to the development of obesity, insulin resistance and fatty liver disease³³. In support of this, previous reports demonstrated that PC was inversely related with insulin resistance^{30,34}, T2DM³⁵ and hepatic steatosis³¹. In our study, PC was not related with any cardiometabolic parameters. This could be due to the small sample size of the study or that our participants were all non-diabetic. Most importantly, carnosine supplementation has been shown to diminish the activity of SREBPs, reduce hepatic triglycerides, and improve insulin sensitivity in mice¹⁹. The beneficial effect of carnosine on PC levels may therefore contribute to the prevention of T2DM and CVD via regulation of SREBP-1 activity.

We find that carnosine supplementation preserved plasma COH levels compared to placebo. A study in people with dyslipidaemia however showed a reduction in COH levels after treatment with simvastatin, as compared to placebo³⁶. Another study also reported lower COH levels in patients with T2DM on statins than in those who were not³⁷. Whilst these studies demonstrate the efficacy of statins in reducing COH levels in individuals with pre-existing altered lipid metabolism, supplementation with carnosine preserved COH levels in obese and overweight people with normal lipid profiles. Related to this, both high and low levels of COH have been shown to increase the risk of T2DM and CVD^{38–40}. COH also has both anti- and pro-inflammatory roles^{41,42}. These indicate that COH has U shape relationship with risk of T2DM and CVD⁴⁰. COH is an essential component of cell membranes and is present in tissues or plasma lipoprotein. COH levels appear to be a physiological constant that may be of considerable value in cholesterol metabolism⁴³. Alterations in cholesterol metabolism could influence COH accumulation⁴⁰. Obesity, insulin resistance and T2DM are associated with changes in cholesterol metabolism⁴⁴. Elevated COH was observed in obesity³⁴ and prediabetes¹⁴. In addition, COH was positively correlated with total and LDL-cholesterols in overweight and obese children⁴⁵. Although we did not find any association between COH levels and cardiometabolic parameters, which could be due to that our participants were all healthy, the observed role of carnosine on COH levels may help to delay the development of T2DM and CVD through improving cholesterol metabolism. Our findings, however, should be confirmed in larger sample sizes.

Strengths and Limitations of the study. The study participants underwent a comprehensive metabolic profiling and were not different at baseline between the groups. Rigorous randomisation process was conducted in addition to blinding of the investigators, study personnel and study participants. We have analysed 24 lipid classes from 324 lipid species. Small sample size of the study could be considered as the main limitations of the study. Due to this, p-values for treatment difference between groups were not corrected for multiple comparisons, and the effect of carnosine on each lipid species were not analysed. Further studies using larger sample sizes are needed to confirm these preliminary findings, and determine the effect of carnosine supplementation on plasma lipid species as well.

Conclusions and Implications for clinical practice. In this exploratory analysis, we have demonstrated for the first time an effect of supplementation with carnosine on THC, PC and COH levels which are likely to have biological roles in the development of insulin resistance, T2DM and CVD. Although lifestyle interventions are effective strategies for prevention and treatment of T2DM and CVD, they are costly and difficult to implement at the population level. Carnosine, a safe and cheap over-the-counter food supplement, may therefore be an effective strategy to prevent or delay the development of insulin resistance and T2DM through improving the plasma lipid profile & metabolism. Future studies in larger sample sizes however are required to confirm these findings as well as to determine the putative effect of carnosine on each plasma lipid species.

Methods and Materials

Study design and population. Details of the trial protocol as well as primary outcomes have been published previously²⁰. In brief, a randomised, double-blind, placebo-controlled trial was conducted in 30 healthy overweight and obese individuals at the Institute of Experimental Endocrinology, Slovak Academy of Sciences, Slovakia. Eligible participants underwent a rigorous medical screening and they were asked to refrain from strenuous exercise and caffeine for 3 days prior to metabolic testing. All participants were non-diabetic as indicated by a 75 g oral glucose tolerance test (OGTT), non-smokers, and healthy according to a physical examination and routine blood analyses. Participants were randomly assigned either to receive 2 g carnosine or identical placebo (2 g sucrose) daily (administered orally in two equivalent doses) for 12 weeks. No participant had signs of infection or took any medication or food supplements at the time of the study. Blood and urine collections were performed after a 12 h overnight fast and 12 h after carnosine ingestion. Participants were asked to refrain from substantial lifestyle changes during the course of the study. As such, participants with weight change ≥ 5 kg in the study period would be excluded from the study. We have excluded 3 participants (1 carnosine, 2 in placebo) for non-compliance with the protocol and 3 (2 carnosine, 1 placebo) participants had missing plasma samples.

All volunteers were recruited from the community and written informed consent was taken prior to study entry. The protocol was approved by the Ethics Committee of the University Hospital Bratislava, Comenius University, Bratislava, Slovakia, and it conforms to the Ethical Declaration of Helsinki.

Anthropometric and blood pressure measurements. Body weight and height were measured and used to calculate body mass index (BMI). Blood pressure was measured in a sitting position after 30 minutes of rest using a Dinamap Compact (Johnson & Johnson Inc., UK). It was recorded three times, separated by 5 minutes, and the mean value was reported.

Assessment of dietary preference and resting energy expenditure. Food preference questionnaire was used to determine the participants' dietary preference for high-fat/low-fat foods based on 72 different food items. Resting energy expenditure (REE) was measured after an overnight fast by indirect calorimetry (Geratherm, Germany).

Metabolic studies. OGTTs were performed after a 12 h overnight fast and blood samples were collected in every 30 minutes for two hours to determine glucose tolerance status (American Diabetes Association criteria, 2006). Serum glucose was analysed using glucosehexokinase 3 kit (Siemens Health Care Diagnostics, Germany) and insulin was determined with immunoradiometric assays (Immunotech, France). Insulin sensitivity and insulin secretion was calculated using homeostatic model assessment of insulin resistance (HOMA-IR) and insulin secretion (HOMA-B) respectively. Total cholesterol, HDL, and triglycerides were measured using diagnostic kits from Roche (Germany). Hypersensitive C - reactive protein (hsCRP) and adiponectin were analysed by an immunoturbidimetric method (Randox, UK).

Measurement of carnosine levels and carnosinase activity. Urinary carnosine was measured using an internal standard and a triple quadrupole (TSQ QUANTUM ULTRA, Thermo Scientific, Italy), as previously described^{20,46}. Serum carnosinase activity was quantified by fluorometric determination of liberated histidine after carnosine addition, and carnosinase content in serum was determined by a sandwich enzyme-linked immunosorbent assay (ELISA) developed by Adelman⁴⁷, and as previously described^{20,48}.

Lipidomic analysis. Lipid analysis was performed by liquid chromatography electrospray ionisation-tandem mass spectrometry using an Agilent 1200 liquid chromatography system combined with an Applied Biosystems API 4000 Q/TRAP mass spectrometer with a turboionspray source (350 °C) and Analyst 1.5 data system at Baker IDI Heart and Diabetes Institute, Australia. The detailed methods of analysis has been previously described elsewhere²⁷. Briefly, plasma samples (10 mL) were randomised (maintaining paired samples at baseline and after intervention), then extracted in a single-phase extraction with 20 volumes of CHCl₃:MeOH (2:1) and 10 mL of an internal standard mix that contained between 50 and 1000 pmol each of 24 non physiologic and stable isotope-labelled lipid standards. The concentration of each lipid species was calculated by relating the peak area of each individual lipid species to the peak area of the corresponding internal standard. The integration of lipid chromatographic peaks was carried out by MassHunter Workstation Software (Agilent Technologies, USA). The concentration of individual lipids was calculated by relating the peak area of each lipid species to the peak area of the corresponding internal standard. A total of 324 lipid species in 24 lipid classes were analysed by multiple reaction monitoring experiments. The totals for each lipid class were calculated by adding the concentrations of individual lipid species within the same class²⁷. Whole plasma was analysed in triplicate and the mean values of each triplicate subsequently used for statistical analysis. Assay performance was monitored by calculating the coefficient of variation (percent) of the quality control plasma samples across the entire analytical run. The median coefficient of variation of the internal standard areas and plasma quality control samples were 10% and 7%, respectively, which indicate that the measurement had good precision ($\leq 15\%$).

Statistical analysis. The sample size calculation was computed based on the primary outcome, insulin sensitivity, and has been reported elsewhere²⁰. Data analyses were performed using Stata V.14 (StatCorp LP, USA). Means and standard deviations were reported, unless otherwise stated. Appropriate data transformations were performed when needed. Independent student t-tests were conducted to compare the baseline participant characteristics between carnosine and placebo groups. Treatment differences between the groups (between-group differences) were compared using analysis of covariance with the use of baseline values as covariates. Pearson correlations were used to determine the relationship between the lipid classes and cardiometabolic parameters. Linear regressions were performed to confirm the presence of the associations between lipid classes and cardiometabolic parameters after taking into account age, sex and BMI differences.

Data availability. The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

References

- Zhou, X., Zhang, W., Liu, X., Zhang, W. & Li, Y. Interrelationship between diabetes and periodontitis: role of hyperlipidemia. *Arch Oral Biol* **60**, 667–674, <https://doi.org/10.1016/j.archoralbio.2014.11.008> (2015).
- Vergani, C. & Lucchi, T. Plasma HDL cholesterol and risk of myocardial infarction. *Lancet* **380**, 1990, author reply 1991, [https://doi.org/10.1016/s0140-6736\(12\)62148-5](https://doi.org/10.1016/s0140-6736(12)62148-5) (2012).
- Meikle, P. J. & Christopher, M. J. Lipidomics is providing new insight into the metabolic syndrome and its sequelae. *Curr Opin Lipidol* **22**, 210–215, <https://doi.org/10.1097/MOL.0b013e3283453dbe> (2011).
- Meikle, P. J., Wong, G., Barlow, C. K. & Kingwell, B. A. Lipidomics: potential role in risk prediction and therapeutic monitoring for diabetes and cardiovascular disease. *Pharmacol Ther* **143**, 12–23, <https://doi.org/10.1016/j.pharmthera.2014.02.001> (2014).
- Stegemann, C. *et al.* Lipidomics profiling and risk of cardiovascular disease in the prospective population-based Bruneck study. *Circulation* **129**, 1821–1831, <https://doi.org/10.1161/circulationaha.113.002500> (2014).

6. Haus, J. M. *et al.* Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance. *Diabetes* **58**, 337–343, <https://doi.org/10.2337/db08-1228> (2009).
7. Stefan, N., Schick, F. & Haring, H. U. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. *N Engl J Med* **371**, 2236–2237, <https://doi.org/10.1056/NEJMc1412427#SA3> (2014).
8. Spener, F., Lagarde, M., Géloën, A. & Record, M. Editorial: What is lipidomics? *European Journal of Lipid Science and Technology* **105**, 481–482, <https://doi.org/10.1002/ejlt.200390101> (2003).
9. Zhao, Y. Y., Miao, H., Cheng, X. L. & Wei, F. Lipidomics: Novel insight into the biochemical mechanism of lipid metabolism and dysregulation-associated disease. *Chem Biol Interact* **240**, 220–238, <https://doi.org/10.1016/j.cbi.2015.09.005> (2015).
10. Hu, C. *et al.* Application of plasma lipidomics in studying the response of patients with essential hypertension to antihypertensive drug therapy. *Mol Biosyst* **7**, 3271–3279, <https://doi.org/10.1039/c1mb05342f> (2011).
11. Kien, C. L. *et al.* A lipidomics analysis of the relationship between dietary fatty acid composition and insulin sensitivity in young adults. *Diabetes* **62**, 1054–1063, <https://doi.org/10.2337/db12-0363> (2013).
12. Kwan, H. Y. *et al.* Lipidomics identification of metabolic biomarkers in chemically induced hypertriglyceridemic mice. *J Proteome Res* **12**, 1387–1398, <https://doi.org/10.1021/pr3010327> (2013).
13. Greig, F. H., Kennedy, S. & Spickett, C. M. Physiological effects of oxidized phospholipids and their cellular signaling mechanisms in inflammation. *Free Radic Biol Med* **52**, 266–280, <https://doi.org/10.1016/j.freeradbiomed.2011.10.481> (2012).
14. Meikle, P. J. *et al.* Plasma lipid profiling shows similar associations with prediabetes and type 2 diabetes. *PLoS One* **8**, e74341, <https://doi.org/10.1371/journal.pone.0074341> (2013).
15. Meikle, P. J. *et al.* Plasma lipidomic analysis of stable and unstable coronary artery disease. *Arterioscler Thromb Vasc Biol* **31**, 2723–2732, <https://doi.org/10.1161/atvbaha.111.234096> (2011).
16. Baye, E. *et al.* Physiological and therapeutic effects of carnosine on cardiometabolic risk and disease. *Amino Acids* **48**, 1131–1149, <https://doi.org/10.1007/s00726-016-2208-1> (2016).
17. Aldini, G. *et al.* The carbonyl scavenger carnosine ameliorates dyslipidaemia and renal function in Zucker obese rats. *J Cell Mol Med* **15**, 1339–1354, <https://doi.org/10.1111/j.1582-4934.2010.01101.x> (2011).
18. Sauerhofer, S. *et al.* L-carnosine, a substrate of carnosinase-1, influences glucose metabolism. *Diabetes* **56**, 2425–2432, <https://doi.org/10.2337/db07-0177> (2007).
19. Mong, M. C., Chao, C. Y. & Yin, M. C. Histidine and carnosine alleviated hepatic steatosis in mice consumed high saturated fat diet. *Eur J Pharmacol* **653**, 82–88, <https://doi.org/10.1016/j.ejphar.2010.12.001> (2011).
20. de Courten, B. *et al.* Effects of carnosine supplementation on glucose metabolism: Pilot clinical trial. *Obesity (Silver Spring)* **24**, 1027–1034, <https://doi.org/10.1002/oby.21434> (2016).
21. Lee, Y. T., Hsu, C. C., Lin, M. H., Liu, K. S. & Yin, M. C. Histidine and carnosine delay diabetic deterioration in mice and protect human low density lipoprotein against oxidation and glycation. *Eur J Pharmacol* **513**, 145–150, <https://doi.org/10.1016/j.ejphar.2005.02.010> (2005).
22. Rashid, I., van Reyk, D. M. & Davies, M. J. Carnosine and its constituents inhibit glycation of low-density lipoproteins that promotes foam cell formation *in vitro*. *FEBS Lett* **581**, 1067–1070, <https://doi.org/10.1016/j.febslet.2007.01.082> (2007).
23. Khan, A. *et al.* Effect of weight loss and exercise on the high-density lipoprotein (HDL) lipidome in individuals with metabolic syndrome (METS). *Atherosclerosis* **241**, e186, <https://doi.org/10.1016/j.atherosclerosis.2015.04.919> (2015).
24. Siebel, A. L. *et al.* Effects of the BET-inhibitor, RVX-208 on the HDL lipidome and glucose metabolism in individuals with prediabetes: A randomized controlled trial. *Metabolism* **65**, 904–914, <https://doi.org/10.1016/j.metabol.2016.03.002> (2016).
25. Xu, Y. H., Barnes, S., Sun, Y. & Grabowski, G. A. Multi-system disorders of glycosphingolipid and ganglioside metabolism. *J Lipid Res* **51**, 1643–1675, <https://doi.org/10.1194/jlr.R003996> (2010).
26. Larsen, P. J. & Tennagels, N. On ceramides, other sphingolipids and impaired glucose homeostasis. *Mol Metab* **3**, 252–260, <https://doi.org/10.1016/j.molmet.2014.01.011> (2014).
27. Weir, J. M. *et al.* Plasma lipid profiling in a large population-based cohort. *J Lipid Res* **54**, 2898–2908, <https://doi.org/10.1194/jlr.P035808> (2013).
28. Everaert, I. *et al.* Low plasma carnosinase activity promotes carnosinemia after carnosine ingestion in humans. *Am J Physiol Renal Physiol* **302**, F1537–F1544, <https://doi.org/10.1152/ajprenal.00084.2012> (2012).
29. Bergheanu, S. C. *et al.* Lipidomic approach to evaluate rosuvastatin and atorvastatin at various dosages: investigating differential effects among statins. *Curr Med Res Opin* **24**, 2477–2487, <https://doi.org/10.1185/03007990802321709> (2008).
30. Newsom, S. A. *et al.* Skeletal muscle phosphatidylcholine and phosphatidylethanolamine are related to insulin sensitivity and respond to acute exercise in humans. *J Appl Physiol (1985)* **120**, 1355–1363, <https://doi.org/10.1152/jappphysiol.00664.2015> (2016).
31. Vance, J. E. & Vance, D. E. Phospholipid biosynthesis in mammalian cells. *Biochem Cell Biol* **82**, 113–128, <https://doi.org/10.1139/o03-073> (2004).
32. Noga, A. A. & Vance, D. E. A gender-specific role for phosphatidylethanolamine N-methyltransferase-derived phosphatidylcholine in the regulation of plasma high density and very low density lipoproteins in mice. *J Biol Chem* **278**, 21851–21859, <https://doi.org/10.1074/jbc.M301982200> (2003).
33. Walker, A. K. *et al.* A conserved SREBP-1/phosphatidylcholine feedback circuit regulates lipogenesis in metazoans. *Cell* **147**, 840–852, <https://doi.org/10.1016/j.cell.2011.09.045> (2011).
34. Graessler, J. *et al.* Top-down lipidomics reveals ether lipid deficiency in blood plasma of hypertensive patients. *PLoS One* **4**, e6261, <https://doi.org/10.1371/journal.pone.0006261> (2009).
35. Rhee, E. P. *et al.* Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. *J Clin Invest* **121**, 1402–1411, <https://doi.org/10.1172/jci44442> (2011).
36. Chen, F. *et al.* The effects of simvastatin treatment on plasma lipid-related biomarkers in men with dyslipidaemia. *Biomarkers* **16**, 321–333, <https://doi.org/10.3109/1354750x.2011.561367> (2011).
37. Feitosa-Filho, G. S., Seydell Tde, M., Feitosa, A. C., Maranhao, R. C. & Ramires, J. A. Lipid transfer to HDL in type-2 diabetic patients: associations with microalbuminuria, statin, and insulin. *Arq Bras Cardiol* **92**, 94–106 (2009).
38. Kockx, M. *et al.* Cholesterol accumulation inhibits ER to Golgi transport and protein secretion: studies of apolipoprotein E and VSVGt. *Biochem J* **447**, 51–60, <https://doi.org/10.1042/bj20111891> (2012).
39. Tabas, I. The role of endoplasmic reticulum stress in the progression of atherosclerosis. *Circ Res* **107**, 839–850, <https://doi.org/10.1161/circresaha.110.224766> (2010).
40. Xu, X., Zhang, A., Li, N., Li, P. L. & Zhang, F. Concentration-Dependent Diversification Effects of Free Cholesterol Loading on Macrophage Viability and Polarization. *Cell Physiol Biochem* **37**, 419–431, <https://doi.org/10.1159/000430365> (2015).
41. Yao, P. M. & Tabas, I. Free cholesterol loading of macrophages is associated with widespread mitochondrial dysfunction and activation of the mitochondrial apoptosis pathway. *J Biol Chem* **276**, 42468–42476, <https://doi.org/10.1074/jbc.M101419200> (2001).
42. Peled, M. & Fisher, E. A. Dynamic Aspects of Macrophage Polarization during Atherosclerosis Progression and Regression. *Front Immunol* **5**, 579, <https://doi.org/10.3389/fimmu.2014.00579> (2014).
43. Sperry, M. The relationship between total and free cholesterol in human blood serum. *J. Biol. Chem* **114**, 125–133 (1936).
44. Miettinen, T. A. & Gylling, H. Cholesterol absorption efficiency and sterol metabolism in obesity. *Atherosclerosis* **153**, 241–248 (2000).
45. Son, H. H. *et al.* Serum sterol profiling reveals increased cholesterol biosynthesis in childhood obesity. *J Steroid Biochem Mol Biol* **149**, 138–145, <https://doi.org/10.1016/j.jsbmb.2015.02.012> (2015).

46. Pfister, F. *et al.* Oral carnosine supplementation prevents vascular damage in experimental diabetic retinopathy. *Cell Physiol Biochem* **28**, 125–136, <https://doi.org/10.1159/000331721> (2011).
47. Adelman, K. *et al.* Different conformational forms of serum carnosinase detected by a newly developed sandwich ELISA for the measurements of carnosinase concentrations. *Amino Acids* **43**, 143–151, <https://doi.org/10.1007/s00726-012-1244-8> (2012).
48. Stegen, S. *et al.* Muscle histidine-containing dipeptides are elevated by glucose intolerance in both rodents and men. *PLoS One* **10**, e0121062, <https://doi.org/10.1371/journal.pone.0121062> (2015).

Acknowledgements

We thank volunteers for the participation in the trial. We thank A/Prof Peter Meikle and his team for conducting the lipidomics analysis, and their assistance in the data analysis. We also thank Professor Wim Derave for performing the carnosinase measurements. This study was supported by the Royal Australasian College of Physicians, Diabetes Australia Research Trust and Foundation for High Blood Pressure Research. Carnosine supplement was received from Flamma SPa, Italy. EB is a recipient of the Monash Graduate and Monash International Postgraduate Scholarships. BdC is supported by a National Heart Foundation Future Leader Fellowship (100864).

Author Contributions

E.B. assisted the lipidomics analysis, analysed and interpreted the data, wrote the first draft of the manuscript and revised the subsequent drafts. B.dC. designed the study, contributed to the data analysis and interpretation, and review of the manuscript. M.PJ.dC. co-designed the study and review of the manuscript. B.U. & J.U. co-designed and performed the clinical study, and review of the manuscript. G.A. contributed to sample analyses and review of the manuscript. S.V., P.K., T.K. contributed to the clinical data acquisition. All authors read and approved the manuscript. The corresponding author had access to all the data and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Additional Information

Competing Interests: The authors declare that they have no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2017